Rough Draft Atlanta on MSN18h
Researchers expect FDA to approve a twice-yearly shot that reduces risk of HIV infection by 96%Roughly 61,000 Georgians live with HIV, the sexually transmitted virus (STI) that can lead to AIDS, and Atlanta ranks in the ...
Irish Independent on MSN4h
Gilead gives its blessing to Poolbeg Pharma’s Hookpia merger dealUS biopharmaceuticals giant Gilead has thrown its weight behind a potential merger of Ireland’s Poolbeg Pharma and Austria ...
Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.
A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.
We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...
Wesley Sundquist’s lab laid foundation for development of a highly effective, long-lasting preventive measure against HIV.
Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...
The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...
China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication ...
GS-2121 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...
CWA Asset Management Group LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.5% in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback